胱抑素C联合肌酐改善GFR估算与临床决策
2024年KDIGO指南推荐联合使用血清肌酐和胱抑素C的方程用于CKD诊断和分期。综述指出,含胱抑素C的方程在偏差和准确性上通常优于仅基于肌酐的方程,并对肾衰竭、心血管疾病和死亡等结局具有更好的预后价值,尤其在肌酐与胱抑素C估算的eGFR差异较大者中。
要点
- 2024 KDIGO指南推荐联合肌酐和胱抑素C方程用于CKD诊断与分期。
- 含胱抑素C方程在偏差和准确性上通常优于仅肌酐方程,预后价值更高。
- 住院、肌肉量显著变化或危重患者中,胱抑素C可能改善GFR估算并早期识别AKI。
核心结论
- 含胱抑素C的方程在GFR估算准确性及预后价值上通常优于仅肌酐方程,但广泛临床应用仍面临障碍。
研究设计与样本
- 综述综合近期证据,探讨胱抑素C在GFR估算、预后效用及临床应用中的作用。
主要发现
- 含胱抑素C方程在多样人群(包括儿童和合并症患者)中偏差和准确性通常优于仅肌酐方程。
- 含胱抑素C方程对肾衰竭伴替代治疗、心血管疾病和死亡等结局的预后价值 consistently 高于仅肌酐方程。
- 在肌酐与胱抑素C估算的eGFR差异较大的个体中,含胱抑素C方程的预后价值优势尤为明显。
- 住院患者及肌肉量显著变化(如体重减轻或危重病)者中,胱抑素C可能改善GFR估算并促进AKI早期发现。
关键数值与推荐
- 2024 KDIGO指南推荐使用整合血清肌酐和胱抑素C的方程用于CKD诊断和分期。
- 胱抑素C用于CKD分期、风险分层和药物剂量调整,尤其在肌酐方程可靠性较低时。
临床怎么用
- 临床实践中,胱抑素C可辅助CKD分期、风险分层和药物剂量调整。
- 在肌酐方程可靠性较低时(如肌肉量异常),应考虑使用含胱抑素C的方程。
- 将胱抑素C纳入风险方程可改善衰弱或eGFR差异较大人群的校准度。
局限性
- 胱抑素C的广泛临床 adoption 面临障碍,包括院内可及性。
- 将胱抑素C整合入风险方程的结果不一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recognizing its clinical utility, the 2024 Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends using equations that integrate serum creatinine and cystatin C for CKD diagnosis and staging. Cystatin C-inclusive equations generally outperform creatinine-based equations in bias and accuracy across diverse populations, including children and patients with comorbidities. Moreover, cystatin C-inclusive equations consistently demonstrate greater prognostic value than creatinine-only equations for clinical outcomes such as kidney failure with replacement therapy, cardiovascular disease, and mortality, particularly in individuals with large differences between creatinine-based and cystatin C-based eGFR. Among hospitalized patients and those undergoing significant changes in muscle mass, such as during weight loss or critical illness, cystatin C may improve GFR estimation and facilitate earlier detection of AKI. In clinical practice, cystatin C informs CKD staging, risk stratification, and medication dosing, particularly in scenarios where creatinine-based equations are less reliable. Although the integration of cystatin C into risk equations has shown mixed results, its inclusion enhances calibration in populations with frailty or large eGFR differences. Emerging evidence also supports the use of cystatin C in cancer care and kidney transplantation. Despite its promise, widespread clinical adoption of cystatin C faces several barriers, including in-house availability. To surmount these barriers, collaboration between nephrology and laboratory services is needed. As evidence grows, cystatin C-based approaches have the potential to transform CKD detection and management. This study synthesizes recent evidence on cystatin C's role in GFR estimation, prognostic utility, and clinical applications, highlighting emerging areas and strategies for its implementation in health care systems.
引用
- Awdishu L, Karger AB, Shlipak MG, et al. Use of Cystatin C in Tandem with Creatinine to Improve GFR Estimation and Clinical Decision Making. J Am Soc Nephrol. 2026. PMID: 42424121. doi:10.1681/ASN.0000001201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。